Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced it has received clearance to proceed with the use of a more potent formulation in its TKM-Ebola Phase I clinical trial, which is expected to begin enrolling patients early next year.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that it has amended its development and commercialization collaboration agreement with Amgen Inc. to extend the period during which Amgen may exercise its option by six months.
Integral Molecular, a leader in membrane protein antibody discovery, announces that it has successfully generated potent antibody antagonists targeting the P2X3 ion channel using the MPS Discovery EngineTM, its proprietary strategy for antibody elicitation and optimization, in conjunction with Crystal Bioscience’s proprietary GEM technology for isolating unique monoclonal antibodies from immunized chickens.
Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced that data from a pre-clinical proof of concept study in Factor VIII-deficient mice were presented in a poster presentation at the 2013 American Society for Hematology (ASH) International Conference in New Orleans.
A UConn research team has found a way to stabilize hemoglobin, the oxygen carrier protein in the blood, a discovery that could lead to the development of stable vaccines and affordable artificial blood substitutes.
Officials at NanCogenics announced today that Co-Founder and Professor of Molecular and Cellular Oncology at the University of Texas M D Anderson Cancer Center, Jim Klostergaard, has accepted an invitation to present a Keynote Forum address at the 3rd International Conference on Nanotek and Expo, being held in Las Vegas, NV, December 2 – 4. Dr. Klostergaard’s lecture is titled, The Magnetic Localization of Drug-Loaded Nanoparticles for Tumor Therapy: Pre-Clinical Validation.
Over 400 scientists worldwide will converge in Singapore for the 3rd Nano Today Conference which will be held at the Biopolis on December 9 to 11, 2013. Organized by Nano Today, a leading journal for nanoscience and nanotechnology, the Institute of Bioengineering and Nanotechnology (IBN) and Elsevier, the three-day conference will showcase the latest research advances in nanostructured materials and systems for diverse applications in areas such as biomedical, electronic, chemical and energy.
NanoViricides, Inc. (the "Company") reports that it has received results of detailed lab analysis studies from the initial non-GLP toxicology studies of intravenously administered FluCide™. No overt adverse safety and toxicology effects were observed in this study of the Company’s optimized FluCide broad-spectrum anti-influenza drug candidate, even at the maximum feasible dose level. These results are consistent with the preliminary findings of this study that the Company has previously reported, and provide greater details of the safety of FluCide.
A nanorobot is a popular term for molecules with a unique property that enables them to be programmed to carry out a specific task. In collaboration with colleagues in Italy and the USA, researchers at Aarhus University have now taken a major step towards building the first nanorobot of DNA molecules that can encapsulate and release active biomolecules.
Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA—both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.